This morning on CNBC's Squawk Box, an interview with Ronald Renaud, CEO of Idenix, provided insight on the FDA clearing Idenix to resume study of its advanced experimental hepatitis C drug.
To see the interview, click the link below:
http://video.cnbc.com/gallery/?video=3000072985
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.